Swedish Orphan Biovitrum AB (LTS:0MTD) Construction In Progress : kr0 Mil (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Swedish Orphan Biovitrum AB Construction In Progress?

Swedish Orphan Biovitrum AB's quarterly construction in progress increased from Sep. 2023 (kr0 Mil) to Dec. 2023 (kr12 Mil) but then declined from Dec. 2023 (kr12 Mil) to Mar. 2024 (kr0 Mil).

Swedish Orphan Biovitrum AB's annual construction in progress declined from Dec. 2021 (kr23 Mil) to Dec. 2022 (kr8 Mil) but then increased from Dec. 2022 (kr8 Mil) to Dec. 2023 (kr12 Mil).

Swedish Orphan Biovitrum AB Construction In Progress Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Construction In Progress Chart

Swedish Orphan Biovitrum AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

8.00

9.00

23.00

8.00

12.00

Swedish Orphan Biovitrum AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Construction In Progress	Get a 7-Day Free Trial															-	-	-	12.00	-

Swedish Orphan Biovitrum AB Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Swedish Orphan Biovitrum AB (LTS:0MTD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (LTS:0MTD) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

SWOBY:USA BIOVF:USA SOBI:Sweden SOBIs:UK B6E:Germany B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (LTS:0MTD) Headlines

No Headlines